Glenmark Pharmaceuticals, the research-driven global pharma company, has announced its Q3 FY26 results, posting strong double-digit growth across key markets.

 

Consolidated revenue for the quarter ended December 31, 2025, reached Rs. 39,006 million, up 15.1% year-on-year from Rs. 33,876 million in the same period last year. India Formulations led the charge with a 22.1% YoY increase to Rs. 12,986 million, while North America revenues climbed 24.2% YoY to Rs. 9,706 million, boosted by out-licensing income for ISB 2001. Europe and Emerging Markets recorded growth of 9.1% and 8.4% YoY, respectively.

 

Profitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million, translating to an EBITDA margin of 22.3%. Profit After Tax (PAT) reached Rs. 4,032 million, up 15.9% YoY, with a PAT margin of 10.3%.

 

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals, said: "We delivered strong double-digit revenue growth in the third quarter, reflecting disciplined execution across markets and keeping us on track to deliver our near-term guidance.

 

"India continued to outperform in our core therapies. In North America, we advanced our portfolio through new launches, pipeline progression, and the positive regulatory outcome at Monroe. Europe and Emerging markets demonstrated improved momentum, supported by our respiratory franchise and expanding global brands.

 

"Our innovative portfolio is shaping up well to become a meaningful growth contributor. RYALTRIS is scaling across markets, WINLEVI is gaining traction in the U.K. and has received approval in Europe. Our partnered oncology assets including QiNHAYO, Trastuzumab Rezetecan and Aumolertinib will strengthen our presence in high-need markets. We are building a more innovation-led Glenmark with a structurally stronger and more sustainable growth trajectory.”

 

Glenmark’s results highlight robust execution across geographies and a growing innovation-led pipeline poised to drive future growth.